Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 6 of 6 results for tafamidis

  1. Tafamidis for treating transthyretin amyloidosis with cardiomyopathy (TA984)

    Evidence-based recommendations on tafamidis (Vyndaqel) for treating transthyretin amyloidosis with cardiomyopathy in adults.

    Technology appraisal guidance
    Published
    19 June 2024
    View recommendations

    Sections for TA984

  2. Vutrisiran for treating transthyretin amyloidosis with cardiomyopathy (TA1115)

    Evidence-based recommendations on vutrisiran (Amvuttra) for wild-type or hereditary transthyretin amyloidosis with cardiomyopathy in adults.

    Technology appraisal guidance
    Published
    10 December 2025
    View recommendations

    Sections for TA1115

  3. Acoramidis for treating transthyretin amyloidosis with cardiomyopathy (TA1121)

    Evidence-based recommendations on acoramidis (Beyonttra) for treating wild-type or hereditary transthyretin amyloidosis with cardiomyopathy in adults.

    Technology appraisal guidance
    Published
    14 January 2026
    View recommendations

    Sections for TA1121

  4. Past appeals and decisions

    Past technology appraisal appeals and decisions

  5. Tafamidis for treating transthyretin amyloidosis with cardiomyopathy (TA696)

    This guidance has been updated and replaced by NICE technology appraisal guidance 984.

    Withdrawn guidance

  6. NICE recommended a new gene therapy, transformative cystic fibrosis medicines and an obesity jab, during election period

    More than 20 pieces of draft and final guidance on a range of medicines and medical conditions were published during the pre-election period.

    News
    Last updated
    10 July 2024